Companies · Other Health Care

Pegasus Development, Inc.

NEW YORK · Other Health Care

Diligence memoA one-page analyst read on Pegasus Development, Inc. — recommendation, valuation, rhythm, risks.
$30.0M
Total raised · real
1
Rounds
Latest step-up
Top 13%
Sector rank · raised
Series B
Latest stage · inferred · Mon Dec 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Pegasus Development, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.55× the median modeled value of Series B Other Health Care companies in 2019–2021 (78 peers) — value vs value, same stage and era.
  • Issuer reports no revenue, yet is modeled well above niche peers.
Dormant
  • Last raise 5.5 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Pegasus Development, Inc. is one of 5376 Other Health Care companies tracked from NEW YORK. By capital raised it ranks in the upper tier (ahead of 88% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
2020
Year incorporated
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries B · 2020-12-14 Raised $30M (real) Modeled valuation $578M (est)$30M$578MSeries B2020

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$30.0M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$578.3M
Base estimate est.
$70.5M
Conservative case
$2.0B
Upside case
$166.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.36×/yr
Annual markup
1.64×/yr upside case
5.5 yr
Elapsed time used
5.5 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
5.5 yr
On record since
2020
First round
1
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 12× above median
This company$30.0M
Sector median$2.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.7× above median
This company$30.0M
Sector median$17.8M
Modeled value — vs sector median (estimate, all stages) 26× above median
This company$578.3M
Sector median$22.1M

Raised more than 88% of sector peers (real $). Modeled value above 94% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #15 of 78.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)KSMS Holdings, LLC · Series B Raised $40.0M · modeled $885.1M (est)Infab HoldCo, Inc. · Series B Raised $36.5M · modeled $807.5M (est)Aquity Holdings, Inc. · Series B Raised $36.0M · modeled $797.6M (est)MHH Management Holdco, LLC · Series B Raised $35.1M · modeled $777.6M (est)Earli Inc. · Series B Raised $40.0M · modeled $756.4M (est)Encore Dermatology, Inc. · Series B Raised $89.6M · modeled $729.9M (est)National Spine & Pain Centers Holdings, LLC · Series B Raised $32.0M · modeled $708.9M (est)In Vitro Sciences, LLC · Series B Raised $31.5M · modeled $697.9M (est)Lotus Parent, Inc. · Series B Raised $31.2M · modeled $690.4M (est)Iron Oak Holdings LLC · Series B Raised $30.0M · modeled $664.6M (est)Squid Ink, Inc. · Series B Raised $30.2M · modeled $620.8M (est)Predict Innovation Investors, Llc · Series B Raised $27.9M · modeled $617.4M (est)Pegasus Development, Inc. (this company) Raised $30.0M · modeled $578.3M (est)Pegasus Development, Inc.
CompanyStageRaised · realValue · estvs peer med.
KSMS Holdings, LLCSeries B$40.0M$885.1M2.37×
Infab HoldCo, Inc.Series B$36.5M$807.5M2.16×
Aquity Holdings, Inc.Series B$36.0M$797.6M2.13×
MHH Management Holdco, LLCSeries B$35.1M$777.6M2.08×
Earli Inc.Series B$40.0M$756.4M2.02×
Encore Dermatology, Inc.Series B$89.6M$729.9M1.95×
National Spine & Pain Centers Holdings, LLCSeries B$32.0M$708.9M1.90×
In Vitro Sciences, LLCSeries B$31.5M$697.9M1.87×
Lotus Parent, Inc.Series B$31.2M$690.4M1.85×
Iron Oak Holdings LLCSeries B$30.0M$664.6M1.78×
Squid Ink, Inc.Series B$30.2M$620.8M1.66×
Predict Innovation Investors, LlcSeries B$27.9M$617.4M1.65×
Pegasus Development, Inc. this companySeries B$30.0M$578.3M1.55×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$30.0M2020-12-14$166.7M$578.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$30.0M2020-12-14
    • First recorded raise — entered as Series B.
Intelligence
Modeled next raise
$48.0M
Modeled next size est.range $31.2M$76.8M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Norman Victor Meier2020-12
Registry & provenance

Pegasus Development, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1836118
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Equum Management Holdings, LLCOther Health CareSeries B$30.0M$478.8Msame sector · same stage
Iron Oak Holdings LLCOther Health CareSeries B$30.0M$664.6Msame sector · same stage
Valence Health, Inc.Other Health CareSeries B$30.0M$664.6Msame sector · same stage
Fresenius Medical Care OKCD, LLCOther Health CareSeries B$30.2M$669.4Msame sector · same stage
Squid Ink, Inc.Other Health CareSeries B$30.2M$620.8Msame sector · same stage
ASP Aspen Holdings LPOther Health CareSeries B$29.7M$657.5Msame sector · same stage
Fresenius Vascular Care San Antonio MSO, LLCOther Health CareSeries B$30.3M$672.2Msame sector · same stage
Goldcup 12446 ABOther Health CareSeries B$29.7M$657.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
CleopatraRX Development, LLCOther Health CarePre-Seed$2.0M84%
Iris Plans, Inc.Other Health CareSeries A$75.7M83%
Odyssey Group International, Inc.Other Health CareSeed$16.3M83%
Spark Biomedical Inc.Other Health CareSeries B$158.7M82%
Louisville Sc LtdOther Health CarePre-Seed$8.3M82%
Gravie, Inc.Other Health CareSeries C$1.3B82%
ArcherDX, Inc.Other Health CareSeries C$35.6M82%
Apollo Med Innovations, Inc.Other Health CarePre-Seed$2.6M82%
Frequently asked
How much funding has Pegasus Development, Inc. raised?
Pegasus Development, Inc. has raised approximately $30.0M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Pegasus Development, Inc.'s estimated valuation?
Provath's modeled valuation for Pegasus Development, Inc. is approximately $578.3M (modeled range $70.5M–$2.0B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Pegasus Development, Inc. at?
Pegasus Development, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Mon Dec 14.
What does Pegasus Development, Inc. do and where is it based?
Pegasus Development, Inc. operates in the Other Health Care sector, based in NEW YORK.
Explore related

See where Pegasus Development, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Pegasus Development, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.